Full-Time

Head – CMC

Peptides and Oligonucleotides

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in biology, chemistry, chemical engineering, or related field. MS or PhD preferred
  • At least 15 years of experience in technical development including prior oligonucleotide and/or peptide process development within the pharmaceutical industry
  • Experience leading global, cross-functional, high performing teams. Prior experience leading or serving on a CMC team preferred
  • Advanced knowledge of cGMP/GLP regulations, ICH, FDA CMC Guidance Documents
  • A strong track record of successful global CMC submissions and approvals
  • Must be able to function independently and influence appropriate stakeholders and recommend scientifically rigorous, phase appropriate, risk-management based solutions to complex technical challenges
  • Experience working with contract manufacturing organizations
  • Excellent communication and teamwork skills
  • Ability to travel internationally up to 10%
Responsibilities
  • Lead CMC teams to identify and prioritize development activities to ensure phase appropriate Module 3 content that supports global clinical filings and registration plans
  • Serve as the technical SME and process owner for drug substance. Working with contract manufacturing organizations, develop scalable and robust manufacturing processes for oligonucleotides and peptide products
  • Author IND and NDA Module 3, Master Batch Records, Validation Plans and Reports
  • Ensure robust regulatory plans for all changes while minimizing risk to product supply
  • Foster effective teamwork and drive project execution. Proactively track critical path activities, anticipate risks, create contingency plans and decision-making exercises in collaboration with project teams. Update project timelines and budgets, communicate progress, and maintain the CMC program plan
  • Regularly interacts with functional areas including Regulatory, Quality, Supply Chain, Commercial, Medical, Clinical, and non-Clinical development
  • Manage external resources including Consultants and Contractors, as needed to deliver projects
  • Travel to global manufacturing sites to support operations and validation activities
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed positive results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in patients with early dementia related to Alzheimer's. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-43%

1 year growth

-45%

2 year growth

-18%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CENTAUR trial results boost AMX0035's potential for ALS treatment.
  • Growing interest in combination therapies could enhance AMX0035's efficacy.
  • Advancements in biomarker research may aid Amylyx's Alzheimer's trials.

What critics are saying

  • Relyvrio's Phase III failure led to market withdrawal, impacting financial stability.
  • 70% workforce reduction may hinder future R&D efforts.
  • Ongoing securities class action lawsuit could damage investor confidence.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's, unlike many competitors.
  • AMX0035 shows promise in multiple conditions, including ALS and Wolfram syndrome.
  • Amylyx's rigorous clinical trials, like CENTAUR and PEGASUS, enhance its credibility.

Help us improve and share your feedback! Did you find this helpful?